EyeGate Pharmaceuticals vs Retispec
EyeGate Pharmaceuticals vs Retispec, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: EyeGate Pharmaceuticals is on 32/100 and Retispec on 58/100.
Where each one leads
EyeGate Pharmaceuticals
- domain rating: 34/100 against 29/100
- funding raised: $45.5M against $11.1M
Retispec
- our overall score: 58/100 against 32/100
- agent readiness: 52/100 against 39/100
At a glance
| Measure | EyeGate Pharmaceuticals | Retispec |
|---|---|---|
| What it is | Clinical-stage specialty pharmaceutical company developing therapeutics and drug delivery systems for ophthalmic diseases. | AI-powered eye exam for early detection of neurodegenerative diseases like Alzheimer's. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | HealthTech, MedTech, AI-Driven Drug Discovery, Clinical Trials |
| Sells toBusiness model | B2B | B2C | B2B2C | B2G | B2B |
| Offering | Software | hardware | services | marketplace | platform | Software, Hardware |
| Founded | 2000 | 2016 |
| Headquarters | Waltham, United States | Oulu, Finland |
| Status | Active | Active |
Size, funding and growth
| Measure | EyeGate Pharmaceuticals | Retispec |
|---|---|---|
| Employees | Not published | 33 |
| Headcount growthLast 12 months | Not published | +15.4% |
| Total funding | $45.5M | $11.1M |
| Latest round | Debt | Series A |
| LinkedIn followers | Not published | 5,258 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | EyeGate Pharmaceuticals | Retispec |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 32/100 | 58/100 |
| Traction | 38/100 | 51/100 |
| Team | 30/100 | 50/100 |
| Community | Not published | 8/100 |
| Search visibility | 5/100 | 37/100 |
| Quality | 35/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | D (52/100) |
| Domain ratingLink authority, 0-100 | 34/100 | 29/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | EyeGate Pharmaceuticals | Retispec |
|---|---|---|
| CDN | Cloudflare | Not detected |
| CMS | WordPress | Wix |
| Analytics | Google Analytics 4, Google Tag Manager | Not detected |
EyeGate Pharmaceuticals vs Retispec: common questions
Which is better, EyeGate Pharmaceuticals or Retispec?
On our 0-100 score Retispec rates higher (58/100 against 32/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do EyeGate Pharmaceuticals and Retispec compare on the numbers?
EyeGate Pharmaceuticals leads on domain rating (34/100 against 29/100), funding raised ($45.5M against $11.1M). Retispec leads on our overall score (58/100 against 32/100), agent readiness (52/100 against 39/100).
Read the full EyeGate Pharmaceuticals review and pricing or the Retispec review and pricing. You can also browse other EyeGate Pharmaceuticals alternatives we track.